Department of Respiratory Medicine, Jinling Hospital, Nanjing University School of Medicine, 305 East Zhongshan Road, Nanjing 210002, China.
Cancer Invest. 2010 Jul;28(6):661-9. doi: 10.3109/07357901003735634.
To evaluate the prognostic value of matrix metalloproteinase2 (MMP-2) expression in patients with non-small cell lung cancer (NSCLC), the electronic database PubMed, EMBASE were searched for relevant articles. The meta-analysis was finally based on 11 studies that included 1,439 patients, and combined HR was 1.66 (95% confidence intervals (CI: 1.37-2.01). Its effect also appeared significant when the analysis was restricted to tumor cell expression and patients with adenocarcinoma (HR 2.08 (95% CI: 1.24-3.48)). This study supported the fact that MMP-2 could be included in further prospective trials studying prognostic factors in NSCLC.
为了评估基质金属蛋白酶 2（MMP-2）表达在非小细胞肺癌（NSCLC）患者中的预后价值，检索了电子数据库 PubMed、EMBASE 中的相关文章。meta 分析最终基于包括 1439 名患者的 11 项研究，合并 HR 为 1.66（95%置信区间（CI）：1.37-2.01）。当分析仅限于肿瘤细胞表达和腺癌患者时，其效果也显得显著（HR 2.08（95%CI：1.24-3.48））。本研究支持 MMP-2 可被纳入进一步研究 NSCLC 预后因素的前瞻性试验的事实。
